HT-29-luc Orthotopic Mouse Model Service for Colon Cancer

The HT-29-luc orthotopic mouse model pairs a luciferase-tagged human colorectal adenocarcinoma line carrying the canonical BRAF V600E driver mutation with anatomically faithful cecal wall implantation, enabling serial, non-invasive tracking of tumor burden and therapeutic response in a BRAF-mutant microenvironment. Alfa Cytology assembles and manages this model with authenticated HT-29-luc cell assets, precision surgical protocols, and integrated bioluminescence imaging, supplying researchers with a dependable framework for evaluating BRAF/EGFR co-targeting strategies, chemotherapeutic regimens, and anti-metastatic interventions in the preclinical setting.

Overview of HT-29-luc Orthotopic Mouse Model for Colon Cancer

The HT-29 cell line was originally isolated in 1964 by J. Fogh from a primary grade II colorectal adenocarcinoma resected from a 44-year-old female patient. Genetically, this line is defined by a BRAF p.V600E activating mutation that drives constitutive MAPK signaling, alongside truncating APC mutations (p.E853Ter and p.T1556NfsTer3), a TP53 p.R273H missense alteration, and a PIK3CA p.P449T variant. HT-29 is classified as microsatellite stable (MSS) with a CpG island methylator phenotype (CIMP) and a hypertriploid karyotype harboring 68–72 chromosomes. Morphologically, the cells present as epithelial-like adherent cells capable of mucin secretion upon differentiation, with a doubling time of approximately 40–60 hours under standard culture conditions. The luciferase-expressing derivative, HT-29-luc, preserves the full parental mutational landscape while enabling quantitative photon flux measurements that correlate with viable tumor biomass in vivo.

Fig 1. NIR-II fluorescence-guided surgery for colorectal peritoneal cancer. (Guo, Xiaoyong, et al., 2023)

When implanted orthotopically into the murine cecal wall or rectal mucosa, HT-29-luc tumors recapitulate the glandular architecture, mucin production, and invasive behavior of human BRAF-mutant colorectal adenocarcinoma. This anatomical configuration preserves the luminal microbiome interface, submucosal vascular plexus, and mesenteric lymphatic drainage routes, thereby supporting spontaneous metastasis to the liver, lung, and peritoneal cavity. The BRAF V600E mutation renders HT-29 intrinsically resistant to single-agent MEK inhibition due to feedback reactivation of EGFR-mediated signaling, yet responsive to dual BRAF/EGFR blockade, 5-fluorouracil, and irinotecan-based regimens. These molecular and pharmacological attributes position the HT-29-luc orthotopic platform as an essential tool for preclinical evaluation of combination therapies targeting the serrated pathway of colorectal carcinogenesis.

Cell Line Information: HT-29-luc

The table below compiles the essential biological, genetic, and technical specifications of the HT-29-luc human colorectal adenocarcinoma cell line, serving as a comprehensive reference for investigators designing preclinical studies in both in vitro and in vivo contexts.

Our Services

Alfa Cytology furnishes a full-spectrum HT-29-luc orthotopic mouse model service calibrated for BRAF-mutant colorectal cancer preclinical research. Our scope encompasses authenticated HT-29-luc master cell bank sourcing, mycoplasma clearance, and expansion under monitored passage limits, followed by precision cecal wall or rectal mucosal surgical implantation in immunocompromised hosts. Longitudinal tumor surveillance is conducted via scheduled IVIS bioluminescence imaging, while endpoint analyses span tumor biometrics, H&E histopathology, mucin staining, immunohistochemistry, and molecular profiling. Each protocol element—from implantation site selection to imaging cadence and tissue triage—is tailored to your compound mechanism and translational goals, yielding datasets suitable for peer-reviewed publication and regulatory dossier compilation.

Workflow of HT-29-luc Orthotopic Mouse Model Construction

Assembly of the HT-29-luc orthotopic colon cancer model necessitates exacting surgical technique, rigorous cell line stewardship, and standardized imaging protocols to ensure consistent engraftment and quantifiable therapeutic readouts. The operational framework described below is executed within specific pathogen-free barrier facilities, advancing through the following sequential stages:

1. Cell Line Authentication and Luciferase Validation: HT-29-luc cells are revived from authenticated cryopreserved master stocks and expanded in McCoy's 5A medium supplemented with 10% heat-inactivated FBS. Prior to surgical deployment, cells undergo mandatory STR identity confirmation, mycoplasma PCR screening, and in vitro luciferase activity validation via D-luciferin substrate assay to verify reporter expression stability and signal linearity across the anticipated cell density range.
2. Host Selection and Preoperative Conditioning: Female or male athymic nude (nu/nu) or NOD/SCID gamma (NSG) mice aged 6–8 weeks are selected based on study design requirements. Animals are housed in specific pathogen-free vivaria under controlled temperature (22 ± 2°C), humidity (50 ± 10%), and a 12-hour light/dark cycle, with ad libitum access to irradiated chow and acidified water. A minimum five-day acclimation period is observed, during which baseline body weights and clinical observations are documented.
3. Anesthesia and Aseptic Surgical Field Establishment: On the day of implantation, mice are anesthetized with 2–3% isoflurane inhalation delivered via nose cone, with anesthetic depth confirmed by absence of pedal withdrawal reflex. The ventral abdominal wall is shaved and sterilized with sequential povidone-iodine and 70% ethanol applications. Sterile surgical drapes are positioned to maintain an aseptic operative field, and ophthalmic ointment is applied to prevent corneal desiccation.
4. Cecal Exposure and Orthotopic Cell Deposition: A 1.0–1.5 cm midline laparotomy is performed to access the peritoneal cavity. The cecum is gently exteriorized using atraumatic forceps and kept hydrated with warm sterile PBS. A single-cell suspension of 2 × 10⁶ viable HT-29-luc cells, resuspended in 25–50 µL of serum-free McCoy's 5A medium mixed 1:1 with growth factor-reduced Matrigel, is loaded into a 1 mL syringe fitted with a 30 G needle. The needle is inserted into the subserosal plane of the cecal wall at the anti-mesenteric border, and the cell suspension is slowly deposited to form a discrete submucosal bleb without mucosal perforation.
5. Hemostasis, Cecal Repositioning, and Abdominal Closure: The injection site is compressed gently with a sterile cotton swab for approximately 3 minutes to ensure hemostasis and prevent cell leakage into the peritoneal cavity. The cecal wall is inspected for integrity, then gently returned to anatomical position within the abdomen. The abdominal musculature is closed with absorbable 5-0 sutures in a continuous pattern, and the skin is apposed with surgical staples or tissue adhesive. Mice are transferred to a warmed recovery chamber and monitored until full ambulatory recovery.
6. Bioluminescence Imaging and Tumor Kinetics Surveillance: Beginning approximately 7–10 days post-implantation, tumor establishment is monitored via non-invasive bioluminescence imaging. Mice receive an intraperitoneal injection of D-luciferin (150 mg/kg) and are imaged under isoflurane anesthesia using an IVIS spectrum system. Photon flux (photons/sec) is quantified within a standardized region of interest, with imaging frequency adjusted to study design—typically twice weekly during the growth phase and weekly during treatment phases. Conventional cohorts are additionally monitored by abdominal palpation and digital caliper measurement of externally palpable masses.
7. Stratified Randomization and Therapeutic Intervention: Once tumors achieve a predetermined bioluminescence signal intensity—typically 10⁶ to 10⁷ photons/sec—mice are stratified by tumor burden and body weight into treatment and vehicle control cohorts. Investigational agents are administered according to predefined dosing regimens, with routes selected based on pharmacokinetic properties and mechanism of action. Concurrent bioluminescence imaging continues to capture real-time therapeutic response kinetics.
8. Necropsy, Triage, and Multi-Platform Endpoint Analysis: At study termination, mice are humanely euthanized under deep anesthesia. The cecum and primary tumor are excised en bloc, photographed, and weighed. Tumor tissue is triaged for formalin fixation and paraffin embedding (H&E, mucin staining, IHC for Ki-67, CD31, phospho-ERK, cleaved caspase-3), snap-freezing for Western blot or RNA-seq, and dissociation for flow cytometric analysis. Metastatic foci in mesenteric lymph nodes, liver, lung, and peritoneum are enumerated macroscopically and confirmed histologically.

Fig 2. HT-29-luc Orthotopic Mouse Model construction workflow.

Case Study-HT-29-luc Orthotopic Mouse Model Development

In a recent preclinical investigation, the HT-29-luc orthotopic model was employed to evaluate the efficacy of a BRAF inhibitor combined with an EGFR-targeting monoclonal antibody in overcoming adaptive resistance mechanisms in BRAF-mutant colorectal cancer. Following cecal wall implantation, tumor-bearing mice were stratified by bioluminescence signal and randomized into combination, BRAF inhibitor monotherapy, EGFR monotherapy, and vehicle control arms. Longitudinal in vivo imaging revealed progressive suppression of tumor photon flux in the combination cohort beginning at day 12 post-treatment initiation, whereas monotherapy arms showed transient stabilization followed by rebound. Terminal histopathological analysis demonstrated markedly reduced Ki-67 proliferation indices and increased apoptotic fractions in combination-treated tumors, alongside sustained attenuation of phospho-ERK and phospho-AKT immunoreactivity. These findings illustrate the translational utility of the HT-29-luc orthotopic platform for discriminating combination synergy from single-agent activity and for generating mechanistic insights into feedback-driven resistance in BRAF-mutant colorectal adenocarcinoma.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your HT-29-luc orthotopic model initiative provides access to a specialized preclinical infrastructure purpose-built for BRAF-mutant colorectal cancer drug development. Our operational strengths include:

• Authenticated HT-29-luc master cell banks with documented STR profiles, mycoplasma negativity, and sustained luciferase expression stability across extended passage ranges.
• Standardized in vitro luciferase linearity assays ensuring quantitative signal-to-cell-number correlation prior to in vivo deployment, safeguarding imaging fidelity throughout the study duration.
• Experienced microsurgical teams proficient in both cecal wall and rectal mucosal orthotopic implantation techniques, achieving high tumor take rates with minimal perioperative complications.
• On-site IVIS bioluminescence imaging infrastructure enabling scheduled longitudinal tumor monitoring with calibrated photon flux quantification and automated region-of-interest analysis.
• Flexible study architectures accommodating monotherapy, combination, and sequential dosing paradigms, with stratified randomization based on real-time bioluminescence tumor burden metrics.
• Comprehensive endpoint triage protocols delivering parallel histopathological, mucin histochemical, immunohistochemical, molecular, and flow cytometric datasets from a single tumor specimen.

Contact Us

If your preclinical program demands a rigorously validated HT-29-luc orthotopic model for evaluating BRAF/EGFR co-targeting strategies, chemotherapeutic combinations, or anti-metastatic agents against colorectal malignancy, the scientific team at Alfa Cytology stands ready to design a customized study framework aligned with your therapeutic targets and regulatory milestones. Reach out to us today to discuss your project parameters, request a detailed service quotation, or arrange a technical consultation with our colorectal cancer model specialists.

For research use only. Not intended for any clinical use.